The metabolic syndrome of vascular risk is threatening large numbers of ever-younger people. To date, the syndrome has been chiefly viewed as a potential risk marker that confers a heightened probability of developing type 2 diabetes and occlusive atherothrombotic disease of large- and medium-sized arteries. Accumulating evidence suggests that the components of the metabolic syndrome may also adversely affect the microvasculature through several inter-related mechanisms. These include the following observations: classic risk factors for macrovascular disease such as high blood pressure and dyslipidaemia also accelerate microvascular complications of diabetes, lesser disturbances of glucose metabolism (i.e. impaired glucose tolerance) may be associated with some forms of microvascular dysfunction, non-glucose intermediary metabolites may promote renovascular hypertension thereby damaging the microvasculature, and insulin resistance appears to be directly associated with microvascular dysfunction. In turn, microvascular complications such as nephropathy and autonomic neuropathy may promote the development and progression of atherosclerosis. We argue that the vascular implications of the metabolic syndrome should be broadened to include the microvasculature. The hypothesis that vascular events can be prevented, or at least deferred, through earlier therapeutic intervention in pre-diabetic subjects with glucose intolerance is amenable to testing in clinical trials.

Keywords:
Metabolic syndrome, Microvasculature, Atherosclerosis, Diabetes mellitus, Impaired glucose tolerance
1.
Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005;365:1415–1428.
2.
Alberti KG, Zimmet P, Shaw J: The metabolic syndrome – a new worldwide definition. Lancet 2005;366:1059–1062.
3.
Grundy SM: Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47:1093–1100.
4.
Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006;21:1–6.
5.
De Ferranti SD, Osganian SK: Epidemiology of paediatric metabolic syndrome and type 2 diabetes mellitus. Diab Vasc Dis Res 2007;4:285–296.
6.
Gardner M, Gardner DW, Sowers JR: The cardiometabolic syndrome in the adolescent. Pediatr Endocrinol Rev 2008;5(suppl 4):964–968.
7.
Bao W, Srinivasan SR, Wattigney WA, Berenson GS: Persistence of multiple cardiovascular risk clustering related to syndrome X from childhood to young adulthood: the Bogalusa Heart Study. Arch Intern Med 1994;154:1842–1847.
8.
Weiss R, Dziura J, Burgert TS, et al: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362–2374.
9.
Pinhas-Hamiel O, Zeitler P: Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet 2007;369:1823–1831.
10.
Pirart J: Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part). Diabete Metab 1977;3:245–256.
11.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–853.
12.
Nathan DM: Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676–1685.
13.
Molitch ME, DeFronzo RA, Franz MJ, et al: Nephropathy in diabetes. Diabetes Care 2004;27(suppl 1):S79–S83.
14.
Jawa A, Kcomt J, Fonseca VA: Diabetic nephropathy and retinopathy. Med Clin North Am 2004;88:1001–1036, xi.
15.
Krishnan AV, Kiernan MC: Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007;35:273–290.
16.
McGowan T, McCue P, Sharma K: Diabetic nephropathy. Clin Lab Med 2001;21:111–146.
17.
Wiernsperger N, Nivoit P, De Aguiar LG, Bouskela E: Microcirculation and the metabolic syndrome. Microcirculation 2007;14:403–438.
18.
Stokes KY, Granger DN: The microcirculation: a motor for the systemic inflammatory response and large vessel disease induced by hypercholesterolaemia? J Physiol 2005;562:647–653.
19.
Stepp DW, Pollock DM, Frisbee JC: Low-flow vascular remodeling in the metabolic syndrome X. Am J Physiol Heart Circ Physiol 2004;286:H964–H970.
20.
Frisbee JC: Hypertension-independent microvascular rarefaction in the obese Zucker rat model of the metabolic syndrome. Microcirculation 2005;12:383–392.
21.
de Jongh RT, Serné EH, Ijzerman RG, de Vries G, Stehouwer CD: Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004;109:2529–2535.
22.
Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ: Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes 2006;55:1436–1442.
23.
Frisbee JC: Obesity, insulin resistance, and microvessel density. Microcirculation 2007;14:289–298.
24.
Kingwell BA, Formosa M, Muhlmann M, Bradley SJ, McConell GK: Type 2 diabetic individuals have impaired leg blood flow responses to exercise: role of endothelium-dependent vasodilation. Diabetes Care 2003;26:899–904.
25.
Bitar MS, Wahid S, Mustafa S, Al-Saleh E, Dhaunsi GS, Al-Mulla F: Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes. Eur J Pharmacol 2005;511:53–64.
26.
Gudbjornsdottir S, Sjostrand M, Strindberg L, Lonnroth P: Decreased muscle capillary permeability surface area in type 2 diabetic subjects. J Clin Endocrinol Metab 2005;90:1078–1082.
27.
Marin P, Andersson B, Krotkiewski M, Bjorntorp P: Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care 1994;17:382–386.
28.
Chung TW, Liu AG, Yu JH: Increased red cell rigidity might affect retinal capillary blood flow velocity and oxygen transport efficiency in type II diabetes. Diabetes Res 1993;23:75–82.
29.
Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597–605.
30.
Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A: Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005;112:179–184.
31.
Krentz AJ, Clough G, Byrne CD: Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes Obes Metab 2007;9:781–791.
32.
Meguid El Nahas A, Bello AK: Chronic kidney disease: the global challenge. Lancet 2005;365:331–340.
33.
Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11:309–317.
34.
Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL: Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004;10:3395–3418.
35.
Keech A, Simes RJ, Barter P, et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–1861.
36.
Tesfaye S, Chatuvedi N, Eaton SEM, et al: Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:592–597.
37.
McGill M, Molyneaux L, Twigg SM, Yue DK: The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications 2008;22:18–23.
38.
Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L: The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001;44:1148–1154.
39.
Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL: Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med 2004;21:252–255.
40.
Abdul-Ghani M, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P: Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. Isr Med Assoc J 2006;8:378–382.
41.
Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A: The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 2006;29:2701–2707.
42.
Cull CA, Jensen CC, Retnakaran R, Holman RR: Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007;116:2119–2126.
43.
Gabir MM, Hanson RL, Dabelea D, et al: Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000;23:1113–1118.
44.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002;25:S5–S20.
45.
Haffner SJ, Cassells H: Hyperglycemia as a cardiovascular risk factor. Am J Med 2003;115(suppl 8A):6S–11S.
46.
Nesto RW: Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 2004;116(suppl 5A):11S–22S.
47.
Gerstein HC, Yusuf S: Dysglycaemia and risk of cardiovascular disease. Lancet 1996;347:949–950.
48.
Khaw KT, Wareham N, Luben R, et al: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001;322:15–18.
49.
Alberti KG: Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998;40(suppl):S3–S8.
50.
Singleton JR, Smith AG, Russell JW, Feldman EL: Microvascular complications of impaired glucose tolerance. Diabetes 2003;52:2867–2873.
51.
Garcia Soriano F, Virag L, Jagtap P, et al: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001;7:108–113.
52.
Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen MR: What does postprandial hyperglycaemia mean? Diabet Med 2004;21:208–213.
53.
Su Y, Liu XM, Sun YM, et al: The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int J Clin Pract 2008;62:877–882.
54.
Nguyen TT, Wong TY: Retinal vascular manifestations of metabolic disorders. Trends Endocrinol Metab 2006;17:262–268.
55.
Wong TY, Duncan BB, Golden SH, et al: Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. Invest Ophthalmol Vis Sci 2004;45:2949–2954.
56.
Kawasaki R, Tielsch JM, Wang JJ, et al: The metabolic syndrome and retinal microvascular signs in a Japanese population: the Funagata study. Br J Ophthalmol 2008;92:161–166.
57.
Lee RH, Dellon AL: Insulin resistance: does it play a role in peripheral neuropathy? Diabetes Care 1999;22:1914–1915.
58.
Krentz AJ, Honigsberger L, Nattrass M: Selection of patients with symptomatic diabetic neuropathy for clinical trials. Diabete Metab 1989;15:416–419.
59.
Cameron NE, Cotter MA: Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997;46(suppl 2):S31–S37.
60.
Singleton JR, Smith AG: Therapy insight: neurological complications of prediabetes. Nat Clin Pract Neurol 2006;2:276–282.
61.
Smith AG, Singleton JR: Impaired glucose tolerance and neuropathy. Neurologist 2008;14:23–29.
62.
Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989;320:1025–1030.
63.
Solomon H, Man JW, Jackson G: Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 2003;89:251–253.
64.
Fung MM, Bettencourt R, Barrett-Connor E: Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 2004;43:1405–1411.
65.
Turner RC: The UK Prospective Diabetes Study: a review. Diabetes Care 1998;21(suppl 3):C35–C38.
66.
Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992;15:815–819.
67.
Alberti KG: Blood metabolites in the diagnosis and treatment of diabetes mellitus. Postgrad Med J 1973;49(suppl 7):955–963.
68.
He W, Miao FJ, Lin DC, et al: Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004;429:188–193.
69.
Lowell BB, Shulman GI: Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384–387.
70.
Serne EH, de Jongh RT, Eringa EC, Ijzerman RG, de Boer MP, Stehouwer CD: Microvascular dysfunction: causative role in the association between hypertension, insulin resistance and the metabolic syndrome? Essays Biochem 2006;42:163–176.
71.
De Jongh RT, Clark AD, Ijzerman RG, Serne EH, De Vries G, Stehouwer CD: Physiological hyperinsulinaemia increases intramuscular microvascular reactive hyperaemia and vasomotion in healthy volunteers. Diabetologia 2004;47:978–986.
72.
Clough G, Turzniecka M, Walter M, et al: Muscle microvascular function in central obesity is related to muscle insulin insenstivity but is not reversed by high-dose statin treatment. Diabetes 2009, E-pub ahead of print.
73.
Bohlen HG: Mechanisms for early microvascular injury in obesity and type II diabetes. Curr Hypertens Rep 2004;6:60–65.
74.
Frisbee JC: Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 2005;289:R307–R316.
75.
de Jongh RT, Serne EH, Ijzerman RG, de Vries G, Stehouwer CD: Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes 2004;53:2873–2882.
76.
Krentz AJ, Singh BM, Hale PJ, Robertson DA, Nattrass M: Basal intermediary metabolism in impaired glucose tolerance and morbid obesity. Diabetes Res 1992;20:51–60.
77.
Trujillo ME, Scherer PE: Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006;27:762–778.
78.
Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH: Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 2007;558:7–13.
79.
Jayasena CN, Bloom SR: Role of gut hormones in obesity. Endocrinol Metab Clin North Am 2008;37:769–787, xi.
80.
Tigno XT, Selaru IK, Angeloni SV, Hansen BC: Is microvascular flow rate related to ghrelin, leptin and adiponectin levels? Clin Hemorheol Microcirc 2003;29:409–416.
81.
Hadjadj S, Pean F, Gallois Y, et al: Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study. Diabetes Care 2004;27:2661–2668.
82.
Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME: Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ 1989;298:564–567.
83.
Leeson CP, Kattenhorn M, Morley R, Lucas A, Deanfield JE: Impact of low birth weight and cardiovascular risk factors on endothelial function in early adult life. Circulation 2001;103:1264–1268.
84.
Goodfellow J, Bellamy MF, Gorman ST, et al: Endothelial function is impaired in fit young adults of low birth weight. Cardiovasc Res 1998;40:600–606.
85.
Martin H, Gazelius B, Norman M: Impaired acetylcholine-induced vascular relaxation in low birth weight infants: implications for adult hypertension? Pediatr Res 2000;47:457–462.
86.
Goh KL, Shore AC, Quinn M, Tooke JE: Impaired microvascular vasodilatory function in 3-month-old infants of low birth weight. Diabetes Care 2001;24:1102–1107.
87.
Norman M, Martin H: Preterm birth attenuates association between low birth weight and endothelial dysfunction. Circulation 2003;108:996–1001.
88.
Williams R, Van Gaal L, Lucioni C: Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002;45:S13–S17.
89.
Haffner S: Diabetes and the metabolic syndrome – when is it best to intervene to prevent? Atheroscler Suppl 2006;7:3–10.
90.
Kim JA, Montagnani M, Koh KK, Quon MJ: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888–1904.
91.
Baron AD: Insulin resistance and vascular function. J Diabetes Complications 2002;16:92–102.
92.
Vincent MA, Clerk LH, Lindner JR, et al: Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004;53:1418–1423.
93.
Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998;97:2213–2221.
94.
Takebayashi K, Aso Y, Inukai T: Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. Metabolism 2004;53:693–699.
95.
Vehkavaara S, Yki-Jarvinen H: 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004;24:325–330.
96.
Tamminen MK, Westerbacka J, Vehkavaara S, Yki-Jarvinen H: Insulin therapy improves insulin actions on glucose metabolism and aortic wave reflection in type 2 diabetic patients. Eur J Clin Invest 2003;33:855–860.
97.
Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005–2016.
98.
Krentz AJ: Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003;5(suppl 1):S19–S27.
99.
Armitage J, Bowman L: Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Curr Opin Lipidol 2004;15:439–446.
100.
Colhoun HM, Betteridge DJ, Durrington PN, et al: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–696.
101.
Mogensen CE, Cooper ME: Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med 2004;21:4–17.
102.
Yamagishi S, Matsui T, Sato T, Takeuchi M: Protective role of pravastatin in the pathogenesis of the metabolic syndrome. Med Hypotheses 2006;66:609–611.
103.
Fegan PG, Shore AC, Mawson D, Tooke JE, MacLeod KM: Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Diabet Med 2005;22:1670–1676.
104.
Kastelein JJ: Refocusing on use of cholesteryl ester transfer protein inhibitors. Am J Cardiol 2007;100:n47–n52.
105.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–713.
106.
McVeigh GE, Plumb R, Hughes S: Vascular abnormalities in hypertension: cause, effect, or therapeutic target? Curr Hypertens Rep 2004;6:171–176.
107.
McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003;91:30H–37H.
108.
Bosch J, Yusuf S, Gerstein HC, et al: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551–1562.
109.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–865.
110.
Wiernsperger NF, Bouskela E: Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab 2003;29:6S77–6S87.
111.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589.
112.
Semple RK, Chatterjee VK, O’Rahilly S: PPAR-gamma and human metabolic disease. J Clin Invest 2006;116:581–589.
113.
Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ: Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463–1480.
114.
Viberti G: Thiazolidinediones – benefits on microvascular complications of type 2 diabetes. J Diabetes Complications 2005;19:168–177.
115.
Forst T, Lubben G, Hohberg C, et al: Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 2005;12:543–550.
116.
Artwohl M, Furnsinn C, Waldhausl W, et al: Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPAR-gamma-independent mechanism. Diabetologia 2005;48:586–594.
117.
Bagi Z, Koller A, Kaley G: PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol 2004;286:H742–H748.
118.
Knowler WC, Barrett-Connor E, Fowler SE, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
119.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105.
120.
Buchanan TA, Xiang AH, Peters RK, et al: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796–2803.
121.
Bell DS: Beta-cell rejuvenation with thiazolidinediones. Am J Med 2003;115(suppl 8A):20S–23S.
122.
Dormandy JA, Charbonnel B, Eckland DJ, et al: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–1289.
123.
Yki-Jarvinen H: The PROactive study: some answers, many questions. Lancet 2005;366:1241–1242.
124.
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–2471.
125.
Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189–1195.
126.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180–1188.
127.
Nesto RW, Bell D, Bonow RO, et al: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108:2941–2948.
128.
Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR: Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820–825.
129.
Grundy SM: Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006;5:295–309.
130.
Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581–2586.
131.
Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med 2004;10:355–361.
132.
Bailey CJ: Drugs on the horizon for diabesity. Curr Diab Rep 2005;5:353–359.
133.
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe Study. Lancet 2005;365:1389–1397.
134.
Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121–2134.
135.
Gelfand EV, Cannon CP: Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006;47:1919–1926.
136.
Simons-Morton DG, Obarzanek E, Cutler JA: Obesity research: limitations of methods, measurements, and medications. JAMA 2006;295:826–828.
137.
Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906–1913.
138.
Arterburn DE, Crane PK, Veenstra DL: The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994–1003.
139.
Wenzel UO, Krebs C: Management of arterial hypertension in obese patients. Curr Hypertens Rep 2007;9:491–497.
140.
Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201–207.
141.
Williams B, Poulter NR, Brown MJ, et al: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139–185.
142.
Redon J, Cifkova R, Laurent S, et al: The metabolic syndrome in hypertension: European Society of Hypertension position statement. J Hypertens 2008;26:1891–1900.
143.
Vergeer M, Bots ML, van Leuven SI, et al: Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515–2522.
144.
Soro-Paavonen A, Forbes JM: Novel therapeutics for diabetic micro- and macrovascular complications. Curr Med Chem 2006;13:1777–1788.
145.
Herman WH, Hoerger TJ, Brandle M, et al: The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:323–332.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.